Table 1.
Characteristics | No. of Patients (N = 65) |
---|---|
Type of transplant | |
Haploidentical/cord blood | 28/37 |
Age, years (range) | 34 (4–57) |
Sex | |
Male/female | 40/25 |
Diagnosis | |
AML/MDS | 29 |
ALL | 20 |
NHL/HD | 13 |
CML/MPD | 2 |
CLL | 1 |
Disease status at transplantation | |
Complete remission (%) | 28 (43%) |
Conditioning chemotherapy | |
FMT ± ATG | 100% |
GVHD prophylaxis | |
T cell depletion with no posttransplant immunosuppression | 28 |
Tacrolimus-based* | 37 |
Number of CD34+ cells infused, median (× 106/kg) | |
Haploidentical SCT patients | 10.5 |
Cord blood transplant patients | 0.11 |
Neutrophil engraftment | |
n (%) | 55 (85%) |
median time,† days (range) | 16 (5–57) |
Platelet engraftment | |
n (%) | 42 (76%) |
median time,‡ days (range) | 29 (7%–134) |
ALC 1000 | |
n (%) | 28 (51%) |
median time, days (range) | 57 (26%–434) |
AML indicates acute myeloid leukemia; MDS, myelodysplastic syndromes; ALL, acute lymphoblastic leukemia; NHL, non-Hodgkin lymphoma; HD, Hodgkin disease; CML, chronic myeloid leukemia; MPD, myeloproliferative disease; CLL, chronic lymphocytic leukemia; FMT, fludarabine, melphalan, and thiotepa conditioning; ATG, antithymocyte globulin; GVHD, graft-versus-host disease; SCT, stem cell transplant; ALC, absolute lymphocyte count; MTX, methotrexate; MMF, mycophenolate mofetil.
Tacrolimus + MTX 22 patients, tacrolimus + MMF 14 patients, tacrolimus alone 1 patient.
Median 13 days for haploidentical and 21 days for cord blood transplant recipients.
Median 12 days for haploidentical and 35 days for cord blood transplant.